Preventing fractures in older patients on ADT

Men with prostate cancer who are 70 years of age or older, and who are starting adjuvant androgen deprivation therapy (ADT) for locally advanced or high-risk localized prostate cancer, should receive a bone mineral density (BMD) test followed by selective bisphosphonate therapy for those with osteoporosis, according to an article in today’s issue of Annals of Internal Medicine. … READ MORE …

The Monday evening news: January 5, 2008

In brief news today there is more on Fosamax (this time being associated with a risk for esophageal cancer) and on CureVac’s early stage trial of CV9103. … READ MORE …

Furore about Fosamax

There has been a lot of media noise in the past few days about two studies suggesting that a drug called alendronate (Fosamax/Merck) may be associated with a significant risk for osteonecrosis of the jaw (ONJ). … READ MORE …

Your Sunday prostate cancer news: September 21

The current report covers news from last Thursday through this morning. (Your editor needed a couple of personal days for some quality time!)

  • The FTC has again sought to stop certain companies from making false advertising claims about cancer cures.
  • A new center is to focus on access to prostate cancer screening and partricipation in clinical trials among African-Americans in South Carolina.
  • An “opinion piece” in the International Herald Tribune addresses lifstyle-related issues and cancer risk.
  • A new study provides 2-year data on the use of Fosamax in prevention of bone loss for men under treatment with hormone therapy for prostate cancer. … READ MORE …